Form 4: Theravance Biopharma Executive Acquires 75,000 Shares
SEC Form 4
Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., acquired 75,000 ordinary shares on February 28, 2025.
Summary
- On February 28, 2025, Brett A. Grimaud, a Senior Vice President, General Counsel, and Secretary at Theravance Biopharma, Inc., acquired 75,000 ordinary shares of the company.
- The shares were acquired at a price of $0.
- Following the transaction, Grimaud directly owns 393,811 ordinary shares of Theravance Biopharma, Inc.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of an insider transaction. The acquisition itself could be seen as mildly positive, but the $0 price suggests it's part of a compensation package.
Positives
- An executive increasing their holdings in the company can be seen as a positive signal.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of transaction: Brett A. Grimaud acquired 75,000 ordinary shares. |
| 03/04/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.